查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
总体基因体学市场：2023年至2028年预测
市场调查报告书
商品编码
1410146

总体基因体学市场：2023年至2028年预测

Metagenomics Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

总体基因体学市场预计在预测期内将以 13.26% 的复合年增长率成长。

总体基因体学是指透过定序直接从环境或临床样本中获得的遗传物质的科学研究。总体基因体学在多个领域都有应用，包括环境研究、临床诊断、药物研发、生物技术、食品和营养研究以及其他专业领域。总体基因体学产业的成长主要是由该领域持续的技术进步以及药物研发和临床诊断的改进所推动的。

蓬勃发展的药物研发正在推动总体基因体学市场的成长。

总体基因体学用于药物研发发现，因为它能够识别新的微生物基因和可能成为潜在候选药物的天然产物。总体基因体学透过分析不同环境中的不同微生物群落，能够发现具有治疗特性的生物活性化合物。鼓励探索开拓的微生物生物多样性的有利政府倡议和投资正在推动人们对透过总体基因体学进行药物研发发现的兴趣。例如，2023 年 3 月，加拿大政府向加拿大关键药物倡议拨款 8,050 万加元（5,900 万美元），以加强亚伯达的药物研究、商业化和製造。

技术进步正在推动总体基因体学市场的扩张

随着定序技术和生物资讯学工具的不断进步使总体基因体学研究更加高效和更具成本效益，总体基因体学行业正在经历显着增长。研究人员和工业界现在可以利用这些尖端工具更深入地研究复杂的微生物群落。例如，2023 年 2 月，Tecan Group 和 Oxford Nanopore Technologies 建立了联合伙伴关係，透过简化高通量、自动化工作流程的流程来增强奈米孔文库的製备。 LSK114 代表了传统定序平台的重大进步，因为它能够对天然长 DNA 片段进行定序。

临床诊断的改进正在推动总体基因体学的发展。

总体基因体学在临床诊断中发挥着重要作用，因为它能够全面了解人体中存在的微生物群落。总体基因体学有助于了解这些微生物与宿主健康之间的相互作用，从而改善疾病识别、治疗策略和个人化医疗。临床诊断领域正在经历快速成长，製药公司和政府的投资增加加速了对总体基因体学的需求。例如，2021 年 11 月，美国卫生与公众服务部 (HHS) 宣布投资 6.5 亿美元用于快速诊断检测，以扩大 COVID-19 检测的范围。

预计亚太地区将主导总体基因体学市场。

由于亚太地区高度重视药物研发和相关投资，预计将占据很大的市场份额。例如，2023年6月，一项新的国家药物研发化学倡议MedChem Australia将启动医学研究未来基金（MRFF），该基金旨在加速药物研发进展并增强国家在药物研发化学方面的能力，接受975万美元。此外，2022年5月，韩国卫生福利部宣布向製药业投资8,778亿韩元（6.93亿美元），以加强新药研发工作并加强製药业的劳动力。

高昂的初始成本限制了总体基因体学市场的成长。

宏基因组研究需要使用最先进的研究设备、先进的定序技术和复杂的资料分析方法，这不可避免地需要大量的资金。对于小型研究机构和公司来说，这些高昂的成本可能是采用总体基因体学作为研究方法的主要障碍。例如，仅全基因组定序的成本就约为 25,000 卢比（338 美元）至 50,000 卢比（676 美元），这进一步增加了科学界更广泛采用的挑战。

公司产品

  • CFX 即时 PCR 检测系统： Bio-Rad 实验室提供 CFX 即时 PCR 检测系统。这些系统结合了 2 至 5 色復用、先进的光学技术以及热感梯度的精确温度控制。具有这些功能的 qPCR 系统能够灵敏、可靠地检测单重和多重即时 PCR 反应，对于寻求准确、高效分析遗传物质的各个领域的研究人员来说非常有价值，它已成为一种工具。
  • QIAGEN CLC Genomics Workbench Premium： QIAGEN CLC Genomics Workbench Premium 提供全面的总体基因体学和微生物组分析工具，以满足不同的生物资讯需求。这种先进的软体有助于对微生物组的详细探索、分离株的表征、支持功能总体基因体学研究以及抗药性细菌的鑑定。凭藉其广泛的功能，CLC Genomics Workbench Premium 成为研究人员寻找强大且多功能工具来揭示复杂微生物群落及其功能的重要解决方案。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章总体基因体学市场：副产品

  • 介绍
  • 套件和试剂
  • 定序和资料分析服务
  • 软体

第六章总体基因体学市场：依技术分类

  • 介绍
  • 霰弹枪序列
  • 16S序列
  • 全基因组序列测定
  • 其他的

第七章总体基因体学市场：依应用分类

  • 介绍
  • 环境
  • 临床诊断
  • 药物研发
  • 生物技术
  • 食品和营养
  • 其他的

第八章总体基因体学市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Bio-Rad Laboratories
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • Novogene Co., Ltd.
  • Promega Corporation
  • QIAGEN
  • Takara Bio, Inc.
  • Oxford Nanopore Technologies
  • F. Hoffmann-La Roche Ltd.
简介目录
Product Code: KSI061616411

The metagenomics market is estimated to grow at a CAGR of 13.26% during the forecast period.

Metagenomics refers to the scientific investigation of genetic material obtained directly from environmental or clinical samples via sequencing. Metagenomics finds diverse applications across various fields, including environmental research, clinical diagnostics, drug discovery, biotechnology, food and nutrition studies, and other specialized areas. Metagenomics industry growth is primarily driven by improved drug discovery and clinical diagnostics, alongside continuous technological advancements in the field.

Booming drug discovery bolsters the metagenomics market growth.

Metagenomics is used in drug discovery due to its ability to identify novel microbial genes and natural products that can serve as potential drug candidates. By analyzing diverse microbial communities in various environments, metagenomics enables the discovery of bioactive compounds with therapeutic properties. Favorable government initiative and investments to encourage the exploration of untapped microbial biodiversity has fuelled the interest in drug discovery through metagenomics. For instance, in March 2023, to bolster drug research, commercialization, and manufacturing in the Alberta province, the Canadian government allocated 80.5 million Canadian dollars ($59 million) to the Canadian Critical Drug Initiative.

Technological advancements drive the metagenomics market expansion.

The metagenomics industry has experienced significant growth owing to continuous advancements in sequencing technologies, and bioinformatics tools which have enhanced the efficiency and cost-effectiveness of metagenomics studies. Researchers and industries can now harness these cutting-edge tools to delve deeper into complex microbial communities. For instance, in February 2023, Tecan Group and Oxford Nanopore Technologies formed a collaborative partnership to enhance nanopore library preparation by streamlining the process for high-throughput and automated workflows. The LSK114 represents a significant advancement over conventional sequencing platforms as it enables the sequencing of native, long fragments of DNA.

Improved clinical diagnostics drive metagenomics growth.

Metagenomics plays a crucial role in clinical diagnostics due to its ability to provide comprehensive insights into the microbial communities present in the human body. Metagenomics aids in understanding the interplay between these microorganisms and the host's health, leading to improved disease identification, treatment strategies, and personalized medicine. The field of clinical diagnostics is experiencing rapid growth, driven by increased investments from pharmaceutical companies, and the government which is accelerating metagenomics demand. For instance, in November 2021, an investment of $650 million in rapid diagnostic testing was announced by the US Department of Health and Human Services (HHS) to expand access to COVID-19 tests.

Asia-Pacific is expected to dominate the metagenomics market.

The Asia Pacific will account for a significant share of the market due to the region's significant focus on drug discovery and the accompanying investments. For instance, in June 2023, MedChem Australia, a new national medicinal chemistry initiative, received $9.75 million from the Medical Research Future Fund (MRFF), which aims to foster advancements in drug discovery and strengthen the country's capabilities in the field of medicinal chemistry. Also, in May 2022, the Korean Ministry of Health and Welfare announced an investment of 877.8 billion won ($693 million) in the pharmaceutical industry, aimed at bolstering research and development efforts for new drugs and strengthening the workforce in the sector.

High initial costs restrain the metagenomics market growth.

Metagenomic research demands the utilization of cutting-edge laboratory equipment, highly advanced sequencing technologies, and intricate data analysis methodologies, which inevitably results in significant financial outlays. For smaller research institutions and companies, these substantial expenses can pose a major obstacle to embracing metagenomics as a research approach. As an illustration, the cost of whole genome sequencing alone can range from approximately 25,000 Rs (USD 338) to 50,000 Rs (USD 676), further contributing to the challenge of broader adoption in the scientific community.

Key Developments

  • April 2023: PacBio, a renowned provider of precise and reliable sequencing solutions, unveiled its latest offering, the high-throughput (HT) Nanobind DNA Extraction kits. These advanced kits have been specifically developed to empower researchers with the ability to efficiently extract high-quality DNA from a diverse array of samples within a high-throughput environment. The kits boast a user-friendly and swift protocol, ensuring seamless compatibility with automation platforms offered by leading providers, further enhancing the efficiency and convenience of the DNA extraction process for researchers.
  • March 2023: Illumina Inc., a prominent player in DNA sequencing and array-based technologies, introduced its latest Illumina Complete Long Read technology-based assay. This high-performance, long-read, human whole-genome sequencing (WGS) assay marks a significant advancement as it grants users the unique capability of accessing both long- and short-read data using a single Illumina instrument. The new technology streamlines the workflow with significantly reduced DNA input requirements, setting it apart from other long-read offerings and making it an innovative and accessible solution for researchers.
  • February 2022: Yorkshire Water, in collaboration with Aqua Enviro, the wastewater technical consultancy owned by SUEZ, introduced an innovative metagenomics project aimed at monitoring and optimizing performance in wastewater treatment works. Through genetic sequencing technology, the project will provide Yorkshire Water with valuable insights into the various bacterial populations at their sites and the factors influencing their efficiency during the EBPR upgrades. This cutting-edge approach promises to enhance their understanding of microbial dynamics, enabling more effective control and management of wastewater treatment processes.

Company Products

  • CFX Real-Time PCR Detection Systems: Bio-Rad Laboratories offers the CFX Real-Time PCR Detection Systems, which are highly robust and adaptable instruments. These systems incorporate 2-5 color multiplexing, advanced optical technology, and precise temperature control with thermal gradients. With their capabilities, the qPCR systems enable sensitive and dependable detection of both singleplex and multiplex real-time PCR reactions, making them a valuable tool for researchers in various fields seeking accurate and efficient analysis of genetic material.
  • QIAGEN CLC Genomics Workbench Premium: The QIAGEN CLC Genomics Workbench Premium provides comprehensive metagenomics and microbiome analysis tools, catering to diverse bioinformatics requirements. This advanced software facilitates in-depth exploration of microbiomes, characterizes isolates, supports functional metagenomics studies, and aids in resistance identification. With its wide array of functionalities, the CLC Genomics Workbench Premium proves to be an indispensable solution for researchers seeking robust and versatile tools to unravel the complexities of microbial communities and their functions.

Segmentation

By Product

  • Kits & Reagents
  • Sequencing & Data Analytics Services
  • Software

By Technology

  • Shotgun Sequencing
  • 16S Sequencing
  • Whole Genome Sequencing
  • Others

By Application

  • Environmental
  • Clinical Diagnostics
  • Drug Discovery
  • Biotechnology
  • Food & Nutrition
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. METAGENOMICS MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Kits & Reagents
  • 5.3. Sequencing & Data Analytics Services
  • 5.4. Software

6. METAGENOMICS MARKET, BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Shotgun Sequencing
  • 6.3. 16S Sequencing
  • 6.4. Whole Genome Sequencing
  • 6.5. Others

7. METAGENOMICS MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Environmental
  • 7.3. Clinical Diagnostics
  • 7.4. Drug Discovery
  • 7.5. Biotechnology
  • 7.6. Food & Nutrition
  • 7.7. Others

8. METAGENOMICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Bio-Rad Laboratories
  • 10.2. Illumina, Inc.
  • 10.3. PerkinElmer, Inc.
  • 10.4. Thermo Fisher Scientific, Inc.
  • 10.5. Novogene Co., Ltd.
  • 10.6. Promega Corporation
  • 10.7. QIAGEN
  • 10.8. Takara Bio, Inc.
  • 10.9. Oxford Nanopore Technologies
  • 10.10. F. Hoffmann-La Roche Ltd.